150 related articles for article (PubMed ID: 31268982)
21. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma.
Duconseil P; Garnier J; Weets V; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2019 Jun; 17(1):95. PubMed ID: 31164144
[TBL] [Abstract][Full Text] [Related]
22. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
[TBL] [Abstract][Full Text] [Related]
23. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer.
Groot VP; Blair AB; Gemenetzis G; Ding D; Burkhart RA; Yu J; Borel Rinkes IHM; Molenaar IQ; Cameron JL; Weiss MJ; Wolfgang CL; He J
Eur J Surg Oncol; 2019 Sep; 45(9):1674-1683. PubMed ID: 31023560
[TBL] [Abstract][Full Text] [Related]
24. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
26. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
27. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study.
Michiels N; Doppenberg D; Groen JV; van Veldhuisen E; Bonsing BA; Busch OR; Crobach ASLP; van Delden OM; van Dieren S; Farina A; de Hingh IHJT; Hurks R; Nederend J; Shahbazi Feshtali S; Tank Y; Vahrmeijer AL; Wasser M; Besselink MG; Mieog JSD;
Ann Surg Oncol; 2023 Jun; 30(6):3455-3463. PubMed ID: 36774435
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
Front Oncol; 2020; 10():41. PubMed ID: 32083002
[TBL] [Abstract][Full Text] [Related]
29. Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon.
Ramaswamy A; Jandyal S; Ostwal V; Engineer R; Lewis S; Bose S; Pande N; Shrikhande SV
Indian J Cancer; 2017; 54(3):530-534. PubMed ID: 29798952
[TBL] [Abstract][Full Text] [Related]
30. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
32. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis.
He C; Wang J; Sun S; Zhang Y; Lin X; Lao X; Cui B; Li S
BMC Cancer; 2019 Apr; 19(1):394. PubMed ID: 31029111
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma.
Argalácsová S; Vočka M; Petruželka L; Ryska M; Záruba P; Krška Z; Frýba V; Ulrych J; Černý V; Tůma T; Hoskovec D
Neoplasma; 2023 Jun; 70(3):468-475. PubMed ID: 37498072
[TBL] [Abstract][Full Text] [Related]
34. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.
Seufferlein T; Hammel P; Delpero JR; Macarulla T; Pfeiffer P; Prager GW; Reni M; Falconi M; Philip PA; Van Cutsem E
Cancer Treat Rev; 2019 Jul; 77():1-10. PubMed ID: 31163334
[TBL] [Abstract][Full Text] [Related]
35. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
36. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
Yoo C; Hwang I; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Lee SK; Kim MH; Byun JH; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Chang HM; Kim KP; Kim SC; Ryoo BY
Ther Adv Med Oncol; 2020; 12():1758835920953294. PubMed ID: 32983266
[TBL] [Abstract][Full Text] [Related]
38. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ
Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296
[TBL] [Abstract][Full Text] [Related]
39. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer.
Zhang C; Wu R; Smith LM; Baine M; Lin C; Reames BN
Am J Surg; 2022 Jul; 224(1 Pt A):51-57. PubMed ID: 34973686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
